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therapy (ART). Our hypothesis is that any association between
STIs and VF would be confounded by drug use.
Methods The OHTN Cohort Study follows people receiving
HIV care in Ontario. STI results and viral load (VL) data
were retrieved via linkage with the provincial laboratory. We
restricted analyses to 2610 MSM who completed>=1 annual
questionnaire in 2008–2014 and had two consecutive VL<50
within a six-month period on ART. VF was defined as a sin-
gle VL>=1000 or two consecutive VLs>=200. Periods of STI
exposure were set around the diagnosis dates for each STI.
We modelled STI diagnosis exposures and drug use as time-
varying covariates on risk of VF using Cox regression adjust-
ing for age, region and income as confounders. Our model
allowed for repeat STI exposures and repeated VF events
using the marginal means/rates model.
Results There were 472 VFs with a 24 month cumulative inci-
dence of 12.1% (95%CI 11.1, 13.1). VFs at time of a new
chlamydia or gonorrhoea infection were close to nil. We did
not observe an increased risk of VF at the time of a new
syphilis infection (HR=1.2 95% CI 0.8, 2.0; aHR=1.1
95% CI 0.7, 1.7). Risk was higher among drug users (non-
injection aHR=1.4 95% CI 1.1, 1.8; injection aHR=1.8
95% CI 1.1, 2.6). There was no significant interaction but
some evidence of positive confounding between syphilis and
VF by drug use.
Conclusion Regardless of drug use, we did not find an associ-
ation between a new STI diagnosis and increased risk of VF
among men on suppressive ART. Our data are limited by pos-
sible misclassification of STI exposures, because not all men
were tested, and among those diagnosed, exact dates of
acquisition were unknown.
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Introduction: Chlamydia trachomatis serotype-L, lymphogra-
nuloma venereum (LGV), is a well-recognised infection among
men who have sex with men in developed nations. In Africa,
LGV is an uncommon but recognised cause of genital ulcer
disease in men and women. The presence of genital infection
in African women is unknown.
Methods In this pilot study we evaluated the presence of C.
trachomatis serotype-L in 55 vaginal specimens that tested
positive for C. trachomatis. These specimens were obtained in
several studies over the period 2012–2016 that recruited
women visiting a mobile health clinic in rural Mopani District
(n=25) and in various settings in Pretoria: a tertiary obstetrics
and gynaecology clinic (n=14), an antiretroviral treatment
(ART) clinic (n=10) and a sexually transmitted infections
(STI) clinic (n=6). Presence of serovar type-L of C. trachoma-
tis was assessed using a targeted PCR assay and confirmed by
whole-genome sequencing (WGS) of DNA from the clinical
specimen.
Results We identified serotype-L C. trachomatis infection by
targeted PCR in 8 cases. All of these women had presented
with vaginal discharge at either the ART (n=5) or STI (n=3)
clinic. Two women had co-infection with Neisseria
gonorrhoeae, two with Mycoplasma genitalium and two with
Trichomonas vaginalis. WGS of 5 specimens confirmed the
presence of the L2 serovar. Also, one mixed infection of sero-
vars L2 and E (minority) was observed.
Conclusion This pilot study demonstrates the presence of
symptomatic cervical infection by C. trachomatis of serotype-
L2 in African women. This confirms one report of (chronic)
genital infection in African women from more than two deca-
des ago. The significance of this observation is to be deter-
mined with regards to virulence, morbidity, distribution across
the population and clinical management in the current context
of the syndromic approach
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Introduction Gepotidacin (GEP), a novel triazaacenaphthylene
antibacterial, inhibits bacterial DNA replication. A Phase 2
study evaluated GEP as a single oral dose (1.5 or 3g) in sub-
jects with urogenital gonorrhoea.
Methods Pre-dose specimens were obtained for culture and
susceptibility testing by agar dilution. Microbiological success
(MS), was culture confirmed eradication of N. gonorrhoeae
(GC) at test-of-cure (TOC), 3–7 days post dose, in the micro-
biological evaluable (ME) population which consisted of all
randomised subjects with culture confirmed urogenital gonor-
rhoea at baseline, who received any dose of GEP and returned
for TOC.
Results Against 69 GC isolates recovered from baseline uro-
genital specimens in the ME population, GEP minimum inhib-
itory concentration [MIC (mg/mL)] range was £0.06–1 and
MIC90 was 0.5. Resistance (R) to comparators were 33%,
28%, 20%, 0%, 0% and 0% for ciprofloxacin (CIP), penicil-
lin, tetracycline, ceftriaxone, cefixime and spectinomycin,
respectively. 2 isolates had elevated azithromycin MICs
(MICs=2). Overall MS was 96% (66/69) in the ME popula-
tion. PK/PD analysis showed 100% (61/61) MS when the free
area under the curve/MIC ratio (fAUC/MIC) was 48. MS
decreased to 63% (5/8) at fAUC/MICs £24. All isolates from
the 3 urogenital failures were CIP-R, had a baseline GEP
MIC=1 and a pre-existing D86N mutation in ParC, a critical
residue in GEP binding. 2 were treated with a 3g GEP dose
(fAUC/MICs=24) and 1 was treated with a 1.5g GEP dose
(fAUC/MIC=12). 5 additional isolates with D86N were MS (2
at GEP MIC=1, 3 at GEP MIC £0.25). Isolates from 2 failed
subjects (3g GEP dose) demonstrated R emergence to GEP
(MICs increased 32 fold) and had an additional mutation
(A92T) in GyrA, also located in GEP binding pocket.
Conclusion Subjects with fAUC/MICs 48 were MS, including
3 with D86N (fAUC/MICs 96). Further study of GEP, in the
treatment of gonorrhoea is warranted, including demonstration
that higher exposures suppress R in key isolate subsets.
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